Lanoxin Md (Digoxin)

Digoxin inhibits the Na⁺/K⁺‑ATPase pump on cardiac cells, leading to increased intracellular calcium. This boost in calcium enhances the strength of heart muscle contractions. Additionally, digoxin increases vagal tone, slowing conduction through the atrioventricular node and helping to regulate heart rate in atrial fibrillation.

The appropriate dose of Lanoxin Md is individualized by the prescribing clinician based on factors such as the patient’s age, renal function, and severity of disease. Dosage adjustments are made to achieve therapeutic serum digoxin concentrations while minimizing toxicity.

Safety data for digoxin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Clinicians should discuss risks and benefits with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the Lanoxin Md product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Digoxin is a cardiac glycoside that directly increases myocardial contractility and provides rate control, unlike many modern heart‑failure agents that primarily modulate neurohormonal pathways (e.g., ACE inhibitors, beta‑blockers). It is often used as an adjunct when symptoms persist despite guideline‑directed therapy, but it requires careful monitoring for toxicity.

Lanoxin Md should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture, heat, and direct sunlight to maintain stability and potency throughout the shelf life.

Lanoxin Md is taken orally, usually with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without consultation.

The most serious risks include cardiac arrhythmias such as ventricular tachycardia, severe bradycardia, and heart block, which can be life‑threatening. Other critical concerns are digoxin toxicity manifested by nausea, visual disturbances, and electrolyte imbalances, particularly low potassium levels.

Digoxin is contraindicated in patients with known hypersensitivity to the drug, those with uncontrolled ventricular arrhythmias, and individuals with severe renal impairment without appropriate dose adjustment. Caution is also advised for patients with existing AV‑node block or severe electrolyte disturbances.